{"filings":[{"id":563117,"accession_number":"0001104659-26-064761","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-05-21T10:03:12+00:00","items":["5.07"],"status":"ready","headline":"Barinthus shareholders approve Scheme of Arrangement with 99.98% support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Court Meeting: 99.98% by value of Scheme Shares voted for the Scheme of Arrangement (24,709,337 for, 3,772 against).","General Meeting: 99.98% of votes cast approved the Scheme Implementation Proposal (24,710,187 for, 3,922 against, 10 abstentions).","Both meetings held May 20, 2026; total Scheme Shares entitled to vote: 40,848,893.","All matters submitted were approved; results are final."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95912,"accession_number":"0001828185-26-000018","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q1 net loss narrows to $5.5M; merger with Clywedog on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.5M ($0.14/shr) vs $19.6M ($0.49/shr) in Q1 2025.","Cash $67.2M at March 31, 2026; post-merger cash runway expected through 2027.","Merger with Clywedog expected mid-2026; combined company to trade as CLYD.","Doug Swirsky appointed CFO effective May 1, 2026.","VTP-1000 celiac trial data from multiple ascending dose portion expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95911,"accession_number":"0001104659-26-046861","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Barinthus appoints Douglas Swirsky as CFO, effective May 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Swirsky appointed Chief Financial Officer and principal accounting officer, effective May 1, 2026.","Previously served as CFO of MaxCyte (2023-2026) and AavantiBio; CEO of Rexahn Pharmaceuticals.","Compensation: $20,000 per month via master services agreement with Grand Strand BioAdvisors LLC.","Company will provide D&O insurance and indemnification on terms no less favorable than other officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109340,"accession_number":"0001104659-26-037698","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Barinthus Bio principal accounting officer Gemma Jones to step down April 30, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gemma Jones, serving as principal accounting officer via CFGI, notified company of resignation effective April 30, 2026.","No successor has been named as of the filing date.","Jones provided services as an employee of CFGI; her departure is from the accounting officer role only.","Company expects transition to be managed internally until a replacement is found."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109339,"accession_number":"0001828185-26-000011","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Barinthus Bio reports FY2025 net loss $66.5M; merger with Clywedog on track for Q2 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Proposed all-stock merger with Clywedog expected to close Q2 2026; combined entity to trade as CLYD.","Cash, cash equivalents & restricted cash $71.9M at Dec 31, 2025, down from $112.4M YoY.","Net loss of $66.5M ($1.64 per share) in 2025 vs $61.1M ($1.55) in 2024.","R&D expenses decreased to $25.6M from $42.2M due to deprioritization of legacy assets.","VTP-1000 multiple ascending dose data in celiac expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109338,"accession_number":"0001104659-26-018283","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Barinthus (BRNS) amends merger with Clywedog: exchange ratios set, timeline extended to June 30, 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Scheme Exchange Ratio set between 0.1 and 0.166667; Merger Exchange Ratio set between 0.000305 and 0.000508.","Post-closing ownership: Beacon shareholders ~34%, Clywedog stockholders ~66% on fully diluted basis.","Beacon minimum cash requirements extended to June 30, 2026 ($20.47M); Clywedog minimum to $1M by May 31, 2026.","Amendment cites unexpected delay from U.S. federal government shutdowns as reason for extended timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109337,"accession_number":"0001828185-26-000004","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Barinthus Biotherapeutics receives Nasdaq delinquency notice over bid price below $1.00 per ADR","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Dec 30, 2025, Nasdaq notified Barinthus that its ADS bid price was below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).","Company has 180 calendar days, until June 29, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.","If not compliant by deadline, a second 180-day period may be available if certain conditions are met; company evaluating options including a reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125817,"accession_number":"0001828185-25-000075","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Barinthus Bio Phase 1 AVALON trial of VTP-1000 shows safety, dose-dependent effect in celiac disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VTP-1000 well-tolerated in SAD portion; no treatment-related serious adverse events.","Dose-dependent pharmacological effect observed across 18 patients in three cohorts.","MAD portion with gluten challenge ongoing; data expected in second half of 2026.","VTP-1000 uses SNAP-TI platform to co-deliver gluten antigens and rapamycin, promoting immune tolerance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125816,"accession_number":"0001828185-25-000071","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q3 net loss $14.6M; all-stock merger with Clywedog","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.6M ($0.36/share) in Q3 2025 vs $21.1M loss in Q2 2025.","Cash and equivalents $75.7M as of Sept 30, down $12.1M from June 30; runway into 2027.","Announced all-stock merger with Clywedog; combined company renamed Clywedog Therapeutics Holdings, ticker CLYD, close expected H1 2026.","VTP-1000 celiac SAD data expected by end 2025; MAD data in H2 2026.","Impairment of $4.7M due to deal valuation; R&D expenses fell to $5.4M from $8.0M QoQ."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142554,"accession_number":"0001104659-25-094754","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Barinthus (BRNS) merges with Clywedog; Clywedog stockholders to own ~66% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Clywedog stockholders will receive ~4.36 Topco shares per Clywedog share; Barinthus shareholders receive 1 Topco share per share.","Clywedog stockholders to own ~66% of combined entity; Barinthus shareholders ~34%.","Topco may launch self-tender offer for up to $27M of its common stock prior to Merger close.","Deal expected to close in H1 2026, subject to shareholder approvals, court sanction, antitrust clearance, and Nasdaq listing.","Voting agreements cover ~25% of Barinthus shares and all Clywedog shares; lock-ups for six months for certain insiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142552,"accession_number":"0001104659-25-075707","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K/A","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio amends 8-K to correct VTP-850 trial statement; reports Q2 net loss of $21.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.1M ($0.52/share) vs $19.7M ($0.49/share) in Q1 2025.","Cash $87.8M, down $12.8M from Q1; runway unchanged into 2027.","R&D expense $8.0M, down from $8.3M; G&A $15.4M, up from $12.6M.","VTP-1000 AVALON MAD initiated, SAD data due early Q4 2025.","Correction: Previous inaccurate sub-bullet on VTP-850 trial result replaced; trial complete, well tolerated, immunogenicity signs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142553,"accession_number":"0001828185-25-000058","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q2 net loss $21.1M ($0.52/share); cash $87.8M, runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents & restricted cash $87.8M at June 30, 2025, down $12.8M from Q1.","Q2 net loss $21.1M vs $19.7M in Q1; diluted EPS -$0.52 vs -$0.49.","R&D expenses $8.0M in Q2, down from $8.3M Q1; VTP-1000 celiac trial lead driver.","Phase 1 AVALON SAD final cohort ongoing; topline data expected early Q4 2025.","MAD portion of AVALON started July 2025; data expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160613,"accession_number":"0001104659-25-058141","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Barinthus Biotherapeutics shareholders approve all proposals at 2025 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Resolutions to re-elect directors Pierre A. Morgon and Joseph C. Scheeren passed with ~98.9% of votes cast.","PricewaterhouseCoopers LLP re-appointed as U.K. statutory auditors and ratified as independent auditor for FY2025.","Shareholders approved director remuneration policy and advisory compensation report for FY2024.","No dividend recommended for FY2024; statutory accounts received and noted.","Quorum achieved with 26,993,016 ordinary shares present or represented (66.9% of entitled shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160612,"accession_number":"0001828185-25-000036","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Barinthus Bio Q1 loss widens to $19.6M; CFO Brown out, CEO Enright takes PFO; presents Phase 2 HBV data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.6M ($0.49/share) vs $15.5M ($0.40) in Q1 2024; R&D spending down to $8.3M from $11.1M.","Cash $100.6M as of Mar 31, down from $112.4M; company expects runway into 2027.","CFO Gemma Brown terminated Apr 30 in restructuring; CEO William Enright named principal financial officer, Brown stays as principal accounting officer until successor.","HBV003 trial: 33% (15/45) of low baseline HBsAg participants achieved ≥1 log decline; 71% met NUC discontinuation criteria; no SAEs.","IM-PROVE II: 25% (2/8) of participants with baseline HBsAg <1000 IU/mL reached functional cure; all seroconverted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178848,"accession_number":"0001828185-25-000018","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio FY2024 net loss $61.1M; cash runway into 2027; VTP-1000 data Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $61.1M ($1.55 per share) vs $73.3M in 2023; goodwill impairment of $12.2M.","Cash $112.4M at Dec 31, 2024, down from $142.1M; expected cash runway into 2027.","Revenue $15.0M from Vaxzevria royalties (no future payments expected).","Lead candidate VTP-1000 (celiac disease) Phase 1 AVALON trial; single ascending dose data expected Q3 2025.","VTP-300 for CHB achieved 8 participants with HBsAg loss, 2 functional cures; Phase 2b data due Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178847,"accession_number":"0001828185-25-000004","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","2.05","5.02","7.01","9.01"],"status":"ready","headline":"Barinthus Bio restructures: cuts 65% workforce, shifts focus to celiac VTP-1000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~65%; plans to close UK site, consolidate operations in Germantown, MD.","CFO Gemma Brown (departing April 30, 2025) and COO Graham Griffiths (June 30, 2025) to leave; severance agreements anticipated.","Prioritizes VTP-1000 (celiac disease) with Phase 1 data expected mid-2025; postpones VTP-300 hepatitis B development until partner found.","Preliminary cash, cash equivalents and restricted cash of $112M as of Dec 31, 2024; cash runway extended to start 2027.","Key 2025 milestones: VTP-1000 SAD data mid-2025; HBV003 and IM-PROVE II results in Q2 2025; VTP-850 prostate cancer data Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195517,"accession_number":"0001828185-24-000093","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Barinthus Bio promotes Geoffrey Lynn to CSO; Nadège Pelletier steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nadège Pelletier to step down as Chief Scientific Officer effective Feb 2, 2025; she served since early 2023.","Geoffrey Lynn, M.D., Ph.D. promoted to CSO effective Dec 1, 2024; he is co-inventor of SNAP-TI technology.","Lynn previously led Avidea Technologies (acquired by Barinthus in 2021) and holds M.D. from Johns Hopkins, D.Phil. from Oxford.","Company highlights pipeline progress: VTP-300 in chronic hepatitis B, VTP-1000 (SNAP-TI) in Phase 1 for celiac disease.","Transition expected to be smooth; Pelletier will remain until responsibilities transitioned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195516,"accession_number":"0001828185-24-000089","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Barinthus/Arbutus HBV data: 23% HBsAg loss with nivolumab; 2 functional cures in Phase 2b","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IM-PROVE II Group C: 23% (3/13) on imdusiran + VTP-300 + low-dose nivolumab achieved HBsAg loss by Week 48.","HBV003: 8 participants achieved HBsAg loss; 2 met functional cure criteria; 2 seroconverted to HBsAb.","In HBV003, 66% (6/9) who discontinued NUCs remained off therapy >6 months, 2 meeting functional cure.","Both regimens were generally well tolerated with no treatment-related SAEs reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195515,"accession_number":"0001828185-24-000083","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q3 net loss narrows to $8.1M on $15M Vaxzevria royalty revenue; cash runway into Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.1M ($0.21/sh) vs $16.9M ($0.43/sh) in Q2; revenue of $15.0M from AstraZeneca Vaxzevria royalty share.","Cash and equivalents $106.1M at Sep 30, 2024, down from $117.8M at Jun 30; cash runway now into Q2 2026.","HBV003 trial of VTP-300 in chronic hepatitis B fully enrolled (121 participants); updated data at AASLD Nov 2024 as late-breaking abstracts.","VTP-1000 Phase 1 AVALON trial in celiac disease initiated; VTP-850 Phase 1 PCA001 trial completed enrollment (22 participants)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":14969000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211782,"accession_number":"0001104659-24-097364","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Barinthus Biotherapeutics promotes Graham Griffiths to COO effective Sept 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Graham Griffiths promoted from Chief Business Officer to COO, effective Sept 1, 2024.","Salary increased to £336,144 in connection with the promotion.","Griffiths joined Barinthus in Oct 2017; previously COO and co-founder of Agalimmune Ltd.","No related party transactions or family relationships with directors or officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211781,"accession_number":"0001828185-24-000073","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q2 2024 net loss $16.9M; prioritizes HBV and celiac programs; CMO hired","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.9M ($0.43 per share) compared to $15.5M ($0.40) in Q1 2024.","Cash $117.8M at June 30, 2024, down from $130.0M at March 31, 2024; runway into Q2 2026.","Pipeline prioritized: VTP-300 (HBV) and VTP-1000 (celiac disease); workforce reduction announced.","Dr. Leon Hooftman appointed Chief Medical Officer effective June 3, 2024.","Upcoming milestones: VTP-1000 Phase 1 first patient dosing in Q3 2024; HBV data updates in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230530,"accession_number":"0001104659-24-070834","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Barinthus prioritizes VTP-300 (CHB) and VTP-1000 (celiac); cuts workforce 25%, extends cash runway to Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pipeline focused on VTP-300 for chronic hepatitis B and VTP-1000 for celiac disease; ongoing Phase 1 trial of VTP-850 in prostate cancer to be completed.","Company to undergo restructuring with workforce reduction of approximately 25% to align resources.","Cash runway expected to extend into second quarter of 2026 due to streamlined pipeline and cost cuts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230529,"accession_number":"0001828185-24-000063","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Barinthus Bio VTP-300 data: 76% eligible to stop NUC therapy; significant HBsAg reduction vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HBV003 (Phase 2b): 76% (16/21) eligible for NUC discontinuation; 19% achieved undetectable HBsAg.","IM-PROVE II (Phase 2a): statistically significant HBsAg reduction at 24 weeks post-EOT (p<0.05) vs placebo.","84% of VTP-300 group (16/19) met criteria to discontinue NUC therapy at EOT vs 52% placebo.","All treatment groups well-tolerated; no SAEs or Grade 3/4 treatment-related AEs in either trial.","Data cutoffs: April 15, 2024 (HBV003) and April 12, 2024 (IM-PROVE II); presented at EASL Congress 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230528,"accession_number":"0001828185-24-000060","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Barinthus shareholders approve all proposals at 2024 AGM, re-elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three directors re-elected: William Enright, Alex Hammacher, Robin Wright with >98% of votes cast.","PricewaterhouseCoopers LLP reappointed as UK statutory auditors and ratified as independent auditor for FY 2024.","Advisory vote on directors' compensation report for FY 2023 passed with ~99.8% approval.","No dividend for FY 2023 as recommended by directors; annual accounts received.","Broker non-votes were ~3 million shares (about 13.6% of quorum) on certain items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230525,"accession_number":"0001828185-24-000046","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K/A","filed_at":"2024-05-14T23:59:59+00:00","items":["7.01","2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q1 net loss $15.5M; VTP-200 misses stat sig; VTP-1000 IND cleared; CMO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss was $15.5M ($0.40/share), compared to $18.2M ($0.48) in Q1 2023; revenue nil.","Cash position $130.0M as of Mar 31, 2024; cash runway into Q4 2025.","VTP-200 Phase 1b/2 APOLLO met safety but no stat sig improvement in hrHPV or lesion clearance vs placebo.","VTP-1000 IND cleared for Phase 1 celiac trial; first patient dosing expected Q3 2024.","Appointed Dr. Leon Hooftman as CMO effective June 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230527,"accession_number":"0001828185-24-000034","cik":1828185,"company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Barinthus Bio Q1 net loss $15.5M ($0.40/sh); cash $130M; VTP-1000 IND cleared for celiac trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to shareholders of $15.5M vs $18.2M in Q1 2023; revenue nil (vs $0.5M).","Cash, cash equivalents and restricted cash of $130.0M as of March 31, 2024; cash runway into Q4 2025.","R&D expenses $11.1M (up from $9.8M), G&A $6.0M (down from $12.1M).","FDA IND clearance received for VTP-1000 Phase 1 trial in celiac disease; first patient dosing expected Q3 2024.","Appointed Dr. Leon Hooftman as CMO, effective June 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28586056.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}